Loading
Latest filing published 30 Nov 2022 for CytoDyn Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Scott A. Kelly (chief executive) discloses dealings in CytoDyn Inc. to SEC (Form 4). Between 16 November 2018 and 30 November 2022, the trades on record add up to 53 filings.
On the open market, the record shows 1 purchase worth €129k and 2 sales worth €7.1M. On balance, insiders were net sellers of €7.0M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 25 share grants and 19 option exercises.
The newest entry dates from 30 November 2022: a share grant, in CytoDyn Inc. The latest purchase dates back some time: it was published 2,363 days ago, on 5 May 2020. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations